GLP-1 Drugs Show Promise in Slowing Alcohol Absorption and Reducing Intoxication

A new study from the Fralin Biomedical Research Institute at Virgina Tech suggests that widely used diabetes and weight-loss medications may also reduce alcohol use by changing how the body processes alcohol. Published recently in Scientific Reports, the research found that GLP-1 agonists—including semaglutide, tirzepatide, and liraglutide—slow the speed at which alcohol enters the bloodstream, resulting in less intense effects on the brain. 

“People who drink know there’s a difference between nursing a glass of wine and downing a shot of whiskey,” said Alex DiFeliceantonio, co-author on the study. “If GLP-1s slow alcohol entering the bloodstream, they could reduce the effects of alcohol and help people drink less.”

Alcohol use remains prevalent among adults in the United States, where more than half report drinking and about one in ten has alcohol use disorder. Chronic drinking is associated with cancer, liver and heart disease, and high blood pressure.

In the study, twenty participants with a BMI of 30 or greater—half maintained on a GLP-1 medication and half not taking any—were tested under controlled conditions. Participants consumed alcohol standardized to achieve a target breath concentration of 0.08 percent. Those using GLP-1 drugs showed slower increases in blood alcohol content and consistently felt less intoxicated, as measured by self-reported scales.

Researchers monitored blood glucose, heart rate, and breath alcohol over several hours, noting that the medication seemed to alter both physiological and subjective responses to alcohol intake. “Other medications designed to help reduce alcohol intake act on the central nervous system,” DiFeliceantonio said. “Our preliminary data suggest that GLP-1s suppress intake through a different mechanism. 

The research was initiated by the late Warren Bickel, director of the Addiction Recovery Research Center, and inspired by earlier observations that individuals taking these drugs often reported reduced alcohol cravings online. First author Fatima Quddos credited Bickel’s guidance as central to its development. “His guidance shaped every stage of this research,” she said.

Findings from this pilot study offer early evidence that GLP-1 drugs may help moderate alcohol use through physiological changes rather than direct effects on brain signaling. Researchers hope larger trials will confirm these results and explore how such drugs could support treatment for alcohol dependence or risky drinking behaviors.